ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01825603
Recruitment Status : Completed
First Posted : April 5, 2013
Last Update Posted : January 30, 2018
Adherex Technologies, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jean Grem, MD, University of Nebraska

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2017
  Actual Study Completion Date : June 2017